News
Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation is designed to improve the function of the tricuspid valve with less morbidity and mortality than conventional surgical valve ...
The original LuX-Valve system was associated with 10.3% mortality and 4.0% hospitalization for heart failure at 1 year when used for transcatheter tricuspid valve replacement (TTVR) in 126 ...
Mitral regurgitation (MR) and tricuspid regurgitation (TR) are two conditions involving backward leakage of blood through a heart valve when a ventricle contracts. People may experience either or ...
Hosted on MSN8mon
Tricuspid Valve Replacement Finds Surer Footing With TRISCEND II's 1-Year Report - MSNThe Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...
Ebstein’s anomaly is a congenital heart defect in which the tricuspid valve leaflets are abnormally displaced toward the cardiac apex resulting in a small right ventricle and massive enlargement ...
ACCESSORY valvular tissue has been described in the subaortic1 and subpulmonic areas2 , 3 and in association with transposition of the great vessels.4 The case reported below represents the second ...
A leaky heart valve refers to a heart valve that does not close properly and cannot repair itself. Treatment usually involves surgery, but it is possible to resolve the issue without surgery. When ...
You grab the leaflets, which are flaps of tissue inside the valve, and pin them together to reduce the leakiness of the tricuspid valve. It’s a tricky procedure.
It clips together a portion of the tricuspid valve’s leaflets, reducing blood backflow, SBCH explained. The minimally invasive approach allows the heart to pump blood more efficiently.
The DUO™ System includes a coaptation valve, an adjustable catheter system and a stent for anchoring. The coaptation valve is positioned between the native tricuspid leaflets to fill the leaky ...
Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment of tricuspid regurgitation (TR).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results